Compare BLDR & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLDR | IONS |
|---|---|---|
| Founded | 1998 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 13.5B |
| IPO Year | 2005 | 1996 |
| Metric | BLDR | IONS |
|---|---|---|
| Price | $104.38 | $81.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 22 |
| Target Price | ★ $134.88 | $85.14 |
| AVG Volume (30 Days) | ★ 2.1M | 1.8M |
| Earning Date | 05-20-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.71 |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $15,190,638,000.00 | N/A |
| Revenue This Year | $2.04 | N/A |
| Revenue Next Year | $5.99 | $50.35 |
| P/E Ratio | ★ $27.05 | $115.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $94.35 | $23.95 |
| 52 Week High | $151.03 | $86.74 |
| Indicator | BLDR | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 37.09 | 46.16 |
| Support Level | $103.53 | $79.78 |
| Resistance Level | $119.52 | $82.85 |
| Average True Range (ATR) | 5.20 | 2.60 |
| MACD | -1.88 | -0.40 |
| Stochastic Oscillator | 12.07 | 27.48 |
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.